Last Updated on October 11, 2024 by The Health Master
The US Food and Drug Administration (USFDA) recently authorised Eli Lilly and Co’s C-19 antibody drug for people aged 12 and older at risk of severe illness, adding a tool that has been found to work against the highly contagious Omicron variant.
The USFDA authorised bebtelovimab for emergency use in patients with mild-to-moderate C-19 who are at high risk of progression to severe disease, including hospitalisation or death.
Bebtelovimab should be used when alternative C-19 treatment options approved or authorised by the USFDA are not accessible or clinically appropriate, the agency said.
The US health regulator had in January revised the Emergency Use Authorisations (EUAs) for Lilly’s antibody combination treatment and a rival therapy from Regeneron after the drugs were found to be ineffective against the Omicron variant.
Lilly has said bebtelovimab retains activity against Omicron as well as its BA. 2 subvariant, which is said to be more transmissible.
The company earlier signed a supply deal with the US government for up to 600,000 doses of bebtelovimab to be delivered by the end of March.
Bebtelovimab was originally discovered by AbCellera Biologics and later licensed and developed by Eli Lilly.
USFDA gives nod to Zydus for Roflumilast Tablets
USFDA gives nod to Lupin for Arformoterol Tartrate inhalation solution
USFDA gives nod to Granules India for generic antidepressant drug
USFDA gives tentative nod to Alembic for Fesoterodine fumarate extended-release tablets
USFDA gives nod to Granules Pharma for potassium chloride for oral solution
USFDA gives nod to Glenmark this for Blood Pressure drug
Govt to make registration certificate mandatory for sale of medical devices
Online portal for submission of Clinical Trial applications: ICMR
USFDA gives nod to Zydus for Roflumilast Tablets
Pharmacist के बिना बिजनेस शुरू करने का मौका, 12वीं पास बेच सकेंगे Medical Devices
Imp: 15 things not to do when using a Rapid Antigen Covid Test
Licenses of two Pharma Companies suspended: NDPS Act
WHO adds this drug to Covid medicines list for severe cases
Govt issues notification on stockpiling of new drug under phase III Clinical trial
Drug alert: 27 out of 1227 samples declared as NSQ in January 2022
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
